HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:

Pirfenidone

		I – idiopathic pulmonary fibrosis ment required after 12 months	
Prerequisites (tick boxes where appropriate)			
(and		scribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health Hospital.	
	(and	D Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist	
	and	O Forced vital capacity is between 50% and 90% predicted	
	and	O Pirfenidone is to be discontinued at disease progression (See Notes)	
	(and	O Pirfenidone is not to be used in combination with subsidised nintedanib	
		O The patient has not previously received treatment with nintedanib	
		O Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or	
		O Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib)	
CONTINUATION – idiopathic pulmonary fibrosis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)			
rerequisites (lick boxes where appropriate)			
and		rescribed by, or recommended by a respiratory specialist, or in accordance with a protocol or guideline that has been endorsed by the Health Z Hospital.	
	(and	C Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment	
	and	O Pirfenidone is not to be used in combination with subsidised nintedanib	
	(O Pirfenidone is to be discontinued at disease progression (See Note)	

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.